Your browser doesn't support javascript.
loading
MAPT allele and haplotype frequencies in Nigerian Africans: population distribution and association with Parkinson's disease risk and age at onset.
Okunoye, Olaitan; Ojo, Oluwadamilola; Abiodun, Oladunni; Abubakar, Sani; Achoru, Charles; Adeniji, Olaleye; Agabi, Osigwe; Agulanna, Uchechi; Akinyemi, Rufus; Ali, Mohammed; Ani-Osheku, Ifeyinwa; Arigbodi, Owotemu; Bello, Abiodun; Erameh, Cyril; Farombi, Temitope; Fawale, Michael; Imarhiagbe, Frank; Iwuozo, Emmanuel; Komolafe, Morenikeji; Nwani, Paul; Nwazor, Ernest; Nyandaiti, Yakub; Obiabo, Yahaya; Odeniyi, Olanike; Odiase, Francis; Ojini, Francis; Onwuegbuzie, Gerald; Osaigbovo, Godwin; Osemwegie, Nosakhare; Oshinaike, Olajumoke; Otubogun, Folajimi; Oyakhire, Shyngle; Ozomma, Simon; Samuel, Sarah; Taiwo, Funmilola; Wahab, Kolawole; Zubair, Yusuf; Hernandez, Dena; Bandres-Ciga, Sara; Blauwendraat, Cornelis; Singleton, Andrew; Houlden, Henry; Hardy, John; Rizig, Mie; Okubadejo, Njideka.
Afiliação
  • Okunoye O; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London WC1N 3BG, United Kingdom.
  • Ojo O; College of Medicine, University of Lagos, and Lagos University Teaching Hospital, Idi Araba, Lagos State, Nigeria.
  • Abiodun O; General Hospital, Isolo, Lagos State, Nigeria.
  • Abubakar S; Ahmadu Bello University, Zaria, Kaduna State, Nigeria.
  • Achoru C; Jos University Teaching Hospital, Jos, Plateau State, Nigeria.
  • Adeniji O; Federal Medical Centre, Abeokuta, Ogun State, Nigeria.
  • Agabi O; College of Medicine, University of Lagos, and Lagos University Teaching Hospital, Idi Araba, Lagos State, Nigeria.
  • Agulanna U; College of Medicine, University of Lagos, and Lagos University Teaching Hospital, Idi Araba, Lagos State, Nigeria.
  • Akinyemi R; Neuroscience and Ageing Research Unit, Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria.
  • Ali M; Federal Teaching Hospital Gombe, Gombe State, Nigeria.
  • Ani-Osheku I; Asokoro District Hospital, Asokoro, Abuja, Nigeria.
  • Arigbodi O; Delta State University, Abraka, Delta State, Nigeria.
  • Bello A; University of Ilorin Teaching Hospital, Ilorin, Kwara State, Nigeria.
  • Erameh C; Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
  • Farombi T; University College Hospital, Ibadan, Oyo State, Nigeria.
  • Fawale M; Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria.
  • Imarhiagbe F; University of Benin, Benin City, Edo State, Nigeria.
  • Iwuozo E; Benue State University, Makurdi, Benue State, Nigeria.
  • Komolafe M; Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria.
  • Nwani P; Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria.
  • Nwazor E; Rivers State University Teaching Hospital, Port Harcourt, Rivers State, Nigeria.
  • Nyandaiti Y; University of Maiduguri Teaching Hospital, Maiduguri, Borno State, Nigeria.
  • Obiabo Y; Federal University of Health Sciences, Otukpo, Benue State, Nigeria.
  • Odeniyi O; General Hospital, Lagos Island, Lagos State, Nigeria.
  • Odiase F; University of Benin, Benin City, Edo State, Nigeria.
  • Ojini F; College of Medicine, University of Lagos, and Lagos University Teaching Hospital, Idi Araba, Lagos State, Nigeria.
  • Onwuegbuzie G; University of Abuja, Abuja, Federal Capital Territory, Nigeria.
  • Osaigbovo G; Jos University Teaching Hospital, Jos, Plateau State, Nigeria.
  • Osemwegie N; University of Port Harcourt, Port Harcourt, Rivers State, Nigeria.
  • Oshinaike O; Lagos State University College of Medicine, Ikeja, Lagos State, Nigeria.
  • Otubogun F; Federal Medical Center, Ebute Metta, Lagos State, Nigeria.
  • Oyakhire S; National Hospital, Abuja, Federal Capital Territory, Nigeria.
  • Ozomma S; University of Calabar Teaching Hospital, Calabar, Cross River State, Nigeria.
  • Samuel S; University of Maiduguri Teaching Hospital, Maiduguri, Borno State, Nigeria.
  • Taiwo F; University College Hospital, Ibadan, Oyo State, Nigeria.
  • Wahab K; University of Ilorin Teaching Hospital, Ilorin, Kwara State, Nigeria.
  • Zubair Y; National Hospital, Abuja, Federal Capital Territory, Nigeria.
  • Hernandez D; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20814, USA.
  • Bandres-Ciga S; Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 20814, USA.
  • Blauwendraat C; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20814, USA.
  • Singleton A; Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 20814, USA.
  • Houlden H; Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20814, USA.
  • Hardy J; Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 20814, USA.
  • Rizig M; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London WC1N 3BG, United Kingdom.
  • Okubadejo N; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London WC1N 3BG, United Kingdom.
medRxiv ; 2023 Mar 24.
Article em En | MEDLINE | ID: mdl-36993627
ABSTRACT

Background:

The microtubule-associated protein tau ( MAPT ) gene is critical because of its putative role in the causal pathway of neurodegenerative diseases including Parkinson's disease (PD). However, there is a lack of clarity regarding the link between the main H1 haplotype and risk of PD. Inconsistencies in reported association may be driven by genetic variability in the populations studied to date. Data on MAPT haplotype frequencies in the general population and association studies exploring the role of MAPT haplotypes in conferring PD risk in black Africans are lacking.

Objectives:

To determine the frequencies of MAPT haplotypes and explore the role of the H1 haplotype as a risk factor for PD risk and age at onset in Nigerian Africans.

Methods:

The haplotype and genotype frequencies of MAPT rs1052553 were analysed using PCR-based KASP™ in 907 individuals with PD and 1,022 age-matched neurologically normal controls from the Nigeria Parkinson's Disease Research (NPDR) network cohort. Clinical data related to PD included age at study, age at onset, and disease duration.

Results:

The frequency of the main MAPT H1 haplotype in this cohort was 98.7% in individuals with PD, and 99.1% in healthy controls (p=0.19). The H2 haplotype was present in 41/1929 (2.1%) of the cohort (PD - 1.3%; Controls - 0.9%; p=0.24). The most frequent MAPT genotype was H1H1 (PD - 97.5%, controls - 98.2%). The H1 haplotype was not associated with PD risk after accounting for gender and age at onset (Odds ratio for H1/H1 vs H1/H2 and H2/H2 0.68 (95% CI0.39-1.28); p=0.23).

Conclusions:

Our findings support previous studies that report a low frequency of the MAPT H2 haplotype in black ancestry Africans, but document its occurrence in the Nigerian population (2.1%). In this cohort of black Africans with PD, the MAPT H1 haplotype was not associated with an increased risk or age at onset of PD.

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article